Table 2.

Distribution of all 216 study eligible patients by comorbidity ^a prevalence and by Phase I patient group ^b

Comorbidity	Phase I patient group
	PC	PE	PT	p-value c
Cardiovascular	79	5	59	0.5349
	(69%)	(71%)	(62%)
Renal disease	7	0	7	0.8668
	(6%)	(0%)	(7%)
Hepatic disease	0	0	1	0.4722
	(0%)	(0%)	(1%)
Hematologic	5	0	1	0.3645
	(4%)	(0%)	(1%)
Endocrine disease	40	2	23	0.2243
	(35%)	(29%)	(24%)
Total patients	131	7	91

^aComorbidities are defined in Table 1 footnotes. Percentages shown are of the column totals.

^bPatients considered (PC) but not enrolled; patients enrolled (PE) but not treated; and patients treated (PT).

^cFrom Fisher's exact test.